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Letters
RESEARCH LETTER
Declining Incidence of Stroke andDementia:
Coincidence or PreventionOpportunity?
Strokeanddementiapose significant threats to theadult brain
and share the same treatable risk factors.1 Stroke incidence in
high-income countries has been declining,2 coinciding with
better risk-factor control. However, hitherto there have been
encouraging trends, but no proof, of declining dementia
incidence.3 To address this, we analyzed health care admin-
istrative data from theCanadian Institute forHealth Informa-
tion for the province of Ontario, Canada.
Methods | We obtained data from the Ontario Health Insur-
ance Plan (OHIP), Ontario Drug Benefit (ODB) Database, Dis-
charge Abstract Database (DAD), and the National Ambula-
toryCareReporting System (NACRS).Weused intercensal and
postcensal projectionsbasedoncensusdata from2001, 2006,
and 2011 to estimate the Ontario population. The OHIP phy-
sicianbillingdatabase captures approximately 98%of all phy-
sician billings for the province of Ontario and includes diag-
nosis and procedure codes. The ODB database identifies
prescription claims for medications covered under the pro-
vincialdrug formulary for individuals agedolder than65years.
The DAD and NACRS databases contain diagnosis and proce-
dure information for all hospital admissions and emergency
departmentvisits inOntario.By law inOntario, all hospital and
emergency department admissions are included in these da-
tabases, so the sampling frame is population-based.
Thisprospective longitudinal population-based studywas
approved by the Sunnybrook Health Sciences Centre Re-
searchEthicsBoard. Patient consentwaswaivedbecausedata
collection for the registry is donewithout patient consent, as
the Institute forClinical Evaluative Sciences is namedas apre-
scribed entity under provincial privacy legislation.
We identified strokes in DAD and NACRS using Interna-
tional Statistical Classification of Diseases and Related Health
Problems, TenthRevision codes I60, I61, I63, and I64andOHIP
codes430,431, 434, and436.Wedefinedacute strokeas 1hos-
pitalization (DAD) or 1 emergency department visit (NACRS)
with amost responsible diagnosis of stroke, or 2 OHIP claims
for physician visits with a diagnosis of stroke within the 365-
Table. Standardized Stroke and Dementia Incidence Rates in Ontario 2002-2013
Fiscal Year Total Events, No. Ontario Population
(Age ≥20 y)
Standardized Incidence Rate
(per 1000 Population)
Standardized Incidence
Rate Change, %
Standardized Incidence
Rate Change, %
Stroke
2002 27 496 8 837 824 3.24 −4.63
−32.4
2003 27 036 8 990 356 3.09 −2.91
2004 27 102 9 139 054 3.00 −2.00
2005 27 354 9 278 839 2.94 −4.08
2006 27 031 9 412 650 2.82 −3.55
2007 26 725 9 526 480 2.72 −5.51
2008 26 069 9 645 342 2.57 −1.95
2009 26 242 9 764 722 2.52 −5.16
2010 25 678 9 907 774 2.39 −4.60
2011 25 273 10 043 234 2.28 −3.07
2012 25 357 10 207 127 2.21 −0.90
2013 25 926 10 351 637 2.19 −4.63
Dementia
2002 42 244 8 784 440 5.39 −1.86
−7.4
2003 42 982 8 932 853 5.29 −1.89
2004 43 817 9 077 583 5.19 +2.89
2005 46 547 9 212 528 5.34 −1.87
2006 46 937 9 341 032 5.24 −1.15
2007 47 724 9 449 484 5.18 +4.25
2008 51 152 9 559 286 5.40 −2.22
2009 51 354 9 670 867 5.28 −1.14
2010 52 308 9 805 265 5.22 −0.96
2011 53 403 9 932 992 5.17 −1.74
2012 54 325 10 089 159 5.08 −1.77
2013 55 340 10 227 315 4.99 −1.86
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day calendar year.Weused International Classification ofDis-
eases, Ninth Revision (290, 294, 331, and 797) and Interna-
tional Statistical Classification of Diseases and Related Health
Problems, Tenth Revision (F00-F03, F05, F06, F09, G30, G31,
and R54) codes from DAD, NACRS, and OHIP, as well as ODB
claims for cholinesterase inhibitors. We defined dementia as
1 hospitalization (DAD) with any field diagnosis of dementia,
1 physician visit with diagnosis of dementia (OHIP), or 1 pre-
scription for cholinesterase inhibitor (ODB) within the previ-
ous year.
We includedpatients aged20years or older, diagnosed as
having stroke between April 1, 2002, andMarch 31, 2014. We
excluded patients with invalid health card numbers, missing
age/sex, and nonresidents of Ontario. We established a look-
back window of 7 years (1995-2001) to exclude cases diag-
nosed before the studyperiod. As a result, any case identified
between April 1, 1995, andMarch 31, 2002, was not counted,
and for each given fiscal year, the individuals with prevalent
dementiawerealso removedfromthedenominator.Caseswith
multiple strokesormultipledementia codesover the studype-
riod contributed only once.We calculated stroke and demen-
tia age- and sex-standardized incident rates per 1000 inhab-
itants for each fiscal year between 2002 and 2013 (12 years).
Results | Between 2002 and 2013, age- and sex-standardized
stroke and dementia incidence rates in the Ontario popula-
tion decreased by 32.4% (P < .001) and 7.4% (P = .009), re-
spectively (Table and Figure).
Discussion |To our knowledge, this is the first study showing a
decline indementia incidence over time. This reportmay also
be unique in showing a corresponding decline in stroke inci-
dence in the samepopulation.Previousevidence suggests that
diet, exercise, cognitive training, and vascular risk monitor-
ing may improve or maintain cognitive functioning in at-risk
elderly people.4 Hence, primary prevention strategies result-
ing in improved risk-factor controlmayhave concurrently re-
duceddementia risk.5 In addition, given that cerebrovascular
disease is an important cause of dementia and that 60 to 80%
of allmajor dementias have a vascular component, the falling
incidence of stroke may have further contributed to the de-
cline in dementia incidence.6
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Long-term Safety and Efficacy ofMexiletine
for PatientsWith SkeletalMuscle Channelopathies
The skeletal muscle channelopathies include the nondystro-
phicmyotoniasandtheperiodicparalyses.Myotonia is thecore
clinical feature of the nondystrophicmyotonias andmay be a
feature of hyperkalemicperiodic paralysis. It is causedbymu-
tations in the skeletal muscle voltage-gated chloride channel
gene CLCN1 or sodium channel gene SCN4A. Adequate treat-
ment ofmyotonia is important for quality of life,mobility, and
functional independence.1 Mexiletine acts on voltage-gated
sodium channels. Its most frequent adverse effect is
gastrointestinal2,3 butminor neurological effects (eg, tremor)
are also reported.4,5 Two randomized clinical trials havedem-
onstrated the efficacy of mexiletine for the short-term treat-
mentofmyotonia2,3but long-termsafetyandefficacydataout-
side a trial setting are lacking. We performed a retrospective
reviewof our large skeletalmuscle channelopathypatient co-
hort to address this.
Methods | All patients with genetically confirmed nondystro-
phic myotonia or hyperkalemic periodic paralysis prescribed
mexiletinewithaminimumof6months follow-up inourclinic
were included. Study data were collected as part of a clinical
audit registeredwith thehospital audit committee. This study
received ethical approval from theNational Hospital for Neu-
rology and Neurosurgery and Institute of Neurology Joint
Research Ethics committee. Because data were collected as
part of a clinical audit, such evaluations do not require pa-
tient consent.
The standard dose titration was increments of 50 to 100
mgofmexiletine perweek until symptoms resolved or a total
daily dose of 600 mg was reached. Efficacy was determined
by patient report. Any symptom or adverse event not clearly
attributable to an alternative cause was included. All avail-
able electrocardiograms (ECGs)were reexamined. Heart rate,
PR interval (P wave to beginning of QRS complex), QRS dura-
tion (Qwave toendof Swave), andcorrectedQT interval (QTc)
were noted or calculatedmanually. The correctedQT interval
was calculated using Medcalc (http://www.medcalc.com/qtc
.html). Significance was assessed using paired t test or 1-way
analysis of variance then unpaired t test.
Results | A total of 122 patients were identified; 63 met inclu-
sion criteria. Forty patients had mutations in CLCN1, 21 in
SCN4A, and 2 in both CLCN1 and SCN4A (subsequently ana-
lyzed with the SCN4A group). The mean length of follow-up
was 4.8 years (range, 6 months to 17.8 years).
Therewere no serious adverse events. Paired assessment
of ECG parameters while not taking mexiletine and at the
highest dose at which an ECG was recorded for each indi-
vidual revealed no significant change in heart rate (71 beats
per minute vs 71 beats per minute; P = .97), PR interval (154
Figure 1. Percentage of Patients Reporting Adverse EventsWhile TakingMexiletine
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A, Any symptom or adverse event
reported while takingmexiletine was
included unless there was a clear
alternative precipitant. Because
some patients reportedmore than
1 adverse event, the total exceeds
100%. B, Distribution of adverse
events by genotype. Because
some patients reportedmore than
1 adverse event, in some cases, the
total exceeds the total number of
patients in that category. CLCN1
missense indicates all patients with
CLCN1missensemutations only
(dominant or recessive myotonia
congenita); heterozygous (Het) NMD,
patients with recessive myotonia
congenita with 1 CLCN1missense
mutation and 1 CLCN1mutation
associated with nonsensemediated
decay; homozygous (Hom) NMD,
patients with recessive myotonia
congenita with 2mutations
associated with nonsensemediated
decay; and SCN4Amissense, all
patients with SCN4Amutations.
a Other adverse effects were
breathlessness (3.1%), vivid dreams
(1.5%), tremor and dizziness (1.5%),
loose stool, change in ejaculate and
fatigue (1.5%), blepharospasm, and
the inability to focus (1.5%).
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